Endonovo’s Breaking Barriers in With Patented Medical Technologies: 2023 Bi-Annual Update
Los Angeles, CA, Aug. 08, 2023 (GLOBE NEWSWIRE) — Endonovo Therapeutics Inc. (OTCQB:ENDV) — commercial developer of medical technology– is proud to announce a series of advancements in the first half of 2023.
Related news for (ENDV)
- Endonovo Closes Asset Purchase Agreement for a Minimum of $50M With SofPulse, Inc
- Endonovo’s SofPulse® to Be Featured at Innovative Pain Management Solutions
- Endonovo Signs Definitive Agreement to Sell SofPulse® Brand Business and IP to SofPulse Inc. for a minimum of $50 Million
- Endonovo’s SofPulse® Secures Taiwan FDA Approval
- Endonovo’s SofPulse® Secures Federal Supply Schedule Inclusion to Accelerate Expansion of VA Distribution